Literature DB >> 11042611

Algorithms for quantitation of protein expression variation in normal versus tumor tissue as a prognostic factor in cancer: Met oncogene expression, and breast cancer as a model.

R T Altstock1, G Y Stein, J H Resau, I Tsarfaty.   

Abstract

BACKGROUND: Immunohistochemistry and immunofluorescence (IF) assays frequently rely on subjective observer evaluation for grading. The aim of our study was to develop an objective quantitative index based on confocal laser scanning microscopy (CLSM) and image analysis of an IF assay to determine alteration in protein expression levels in normal versus tumor tissue. The relative levels of Met expression, a prognostic factor in breast cancer, were used as a model for evaluating image analysis algorithms.
METHODS: Primary human breast cancer biopsies were collected. Sections containing tumor and adjacent uninvolved normal regions were immunostained for Met and digital images were acquired by CLSM. Subsequently, the digital data were manipulated using several different algorithms to calculate prognostic indexes. The results were correlated with the clinical outcome to determine the prognostic value of these indexes.
RESULTS: Different algorithms were used to obtain quantitative indexes to evaluate the relative levels of Met expression. We report a statistical correlation between patient prognosis and relative Met level in normal versus tumor tissue as determined by three distinct algorithms using Kaplan-Meier analysis (log-rank): calculations based on intensity levels differences DV (P = 0.002), DIntensity (P = 0.014), and entropy divergence (Dentropy; P = 0.0023).
CONCLUSIONS: Using adjacent normal tissue as an internal reference, a quantitative index of tumor Met level divergence can be objectively determined to have a prognostic value. Moreover, this methodology can be used for other proteins in a variety of different diseases. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11042611

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  5 in total

1.  In vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met.

Authors:  Sharon Moshitch-Moshkovitz; Galia Tsarfaty; Dafna W Kaufman; Gideon Y Stein; Keren Shichrur; Eddy Solomon; Robert H Sigler; James H Resau; George F Vande Woude; Ilan Tsarfaty
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

2.  Human endogenous retrovirus (HERV-K) reverse transcriptase as a breast cancer prognostic marker.

Authors:  Maya Golan; Amnon Hizi; James H Resau; Neora Yaal-Hahoshen; Hadar Reichman; Iafa Keydar; Ilan Tsarfaty
Journal:  Neoplasia       Date:  2008-06       Impact factor: 5.715

Review 3.  Phage display screening of therapeutic peptide for cancer targeting and therapy.

Authors:  Phei Er Saw; Er-Wei Song
Journal:  Protein Cell       Date:  2019-05-28       Impact factor: 14.870

4.  A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings.

Authors:  Beatrice S Knudsen; Ping Zhao; James Resau; Sandra Cottingham; Ermanno Gherardi; Eric Xu; Bree Berghuis; Jennifer Daugherty; Tessa Grabinski; Jose Toro; Troy Giambernardi; R Scot Skinner; Milton Gross; Eric Hudson; Eric Kort; Ernst Lengyel; Aviva Ventura; Richard A West; Qian Xie; Rick Hay; George Vande Woude; Brian Cao
Journal:  Appl Immunohistochem Mol Morphol       Date:  2009-01

5.  Met kinetic signature derived from the response to HGF/SF in a cellular model predicts breast cancer patient survival.

Authors:  Gideon Y Stein; Nir Yosef; Hadar Reichman; Judith Horev; Adi Laser-Azogui; Angelique Berens; James Resau; Eytan Ruppin; Roded Sharan; Ilan Tsarfaty
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.